Moderna (MRNA) updates 2025 expected revenue range to $1.5 to 2.5 billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025 7:02 AM ESTAchieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)
Updates 2025 expected revenue range to $1.5 to 2.5 billion
Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billion
Updates 2025 expected ending cash balance to approximately $6.0 billion
Anticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts
CAMBRIDGE, MA / ACCESSWIRE / January 13, 2025 / Moderna, Inc. (NASDAQ: MRNA) today... More
